MX2023015016A - Pirrolo[2,3-d]pirimidinas sustituidas, su preparacion y su aplicacion terapeutica. - Google Patents
Pirrolo[2,3-d]pirimidinas sustituidas, su preparacion y su aplicacion terapeutica.Info
- Publication number
- MX2023015016A MX2023015016A MX2023015016A MX2023015016A MX2023015016A MX 2023015016 A MX2023015016 A MX 2023015016A MX 2023015016 A MX2023015016 A MX 2023015016A MX 2023015016 A MX2023015016 A MX 2023015016A MX 2023015016 A MX2023015016 A MX 2023015016A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrimidines
- preparation
- therapeutic application
- compounds
- substituted pyrrolo
- Prior art date
Links
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 abstract 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21315095.6A EP4105218A1 (en) | 2021-06-15 | 2021-06-15 | Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application |
| EP22315117 | 2022-06-02 | ||
| PCT/EP2022/066231 WO2022263472A1 (en) | 2021-06-15 | 2022-06-14 | Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023015016A true MX2023015016A (es) | 2024-05-31 |
Family
ID=82214141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023015016A MX2023015016A (es) | 2021-06-15 | 2022-06-14 | Pirrolo[2,3-d]pirimidinas sustituidas, su preparacion y su aplicacion terapeutica. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240383901A1 (https=) |
| EP (1) | EP4355748A1 (https=) |
| JP (1) | JP2024525150A (https=) |
| KR (1) | KR20240021910A (https=) |
| AU (1) | AU2022294022A1 (https=) |
| BR (1) | BR112023025042A2 (https=) |
| CA (1) | CA3223786A1 (https=) |
| CO (1) | CO2024000083A2 (https=) |
| IL (1) | IL309195A (https=) |
| MX (1) | MX2023015016A (https=) |
| WO (1) | WO2022263472A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025141029A1 (en) * | 2023-12-27 | 2025-07-03 | Sanofi | Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application |
| KR20250163526A (ko) | 2024-05-14 | 2025-11-21 | 김성우 | 음전하 증폭장치가 장착된 어싱용 발판 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2988722B1 (fr) * | 2012-04-03 | 2014-05-09 | Sanofi Sa | Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques |
| CN106146515B (zh) * | 2015-04-17 | 2020-09-04 | 常州隆赛医药科技有限公司 | 新型激酶抑制剂的制备及应用 |
| US11214565B2 (en) * | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| JP2018537502A (ja) * | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法 |
| EP3587422A4 (en) | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE |
| WO2020092136A1 (en) * | 2018-10-31 | 2020-05-07 | Merck Sharp & Dohme Corp. | N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
| EP3915985A4 (en) | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES |
-
2022
- 2022-06-14 US US18/569,790 patent/US20240383901A1/en active Pending
- 2022-06-14 CA CA3223786A patent/CA3223786A1/en active Pending
- 2022-06-14 MX MX2023015016A patent/MX2023015016A/es unknown
- 2022-06-14 EP EP22733628.6A patent/EP4355748A1/en active Pending
- 2022-06-14 KR KR1020247001337A patent/KR20240021910A/ko active Pending
- 2022-06-14 JP JP2023577130A patent/JP2024525150A/ja active Pending
- 2022-06-14 IL IL309195A patent/IL309195A/en unknown
- 2022-06-14 BR BR112023025042A patent/BR112023025042A2/pt unknown
- 2022-06-14 WO PCT/EP2022/066231 patent/WO2022263472A1/en not_active Ceased
- 2022-06-14 AU AU2022294022A patent/AU2022294022A1/en active Pending
-
2024
- 2024-01-05 CO CONC2024/0000083A patent/CO2024000083A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240021910A (ko) | 2024-02-19 |
| IL309195A (en) | 2024-02-01 |
| BR112023025042A2 (pt) | 2024-02-27 |
| AU2022294022A1 (en) | 2024-02-01 |
| CA3223786A1 (en) | 2022-12-22 |
| CO2024000083A2 (es) | 2024-04-08 |
| EP4355748A1 (en) | 2024-04-24 |
| JP2024525150A (ja) | 2024-07-10 |
| WO2022263472A1 (en) | 2022-12-22 |
| US20240383901A1 (en) | 2024-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002562A1 (es) | (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| ECSP19076732A (es) | Compuestos de heteroarilo bicíclicos 66 fusionados y su uso como inhibidores de lats | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| CO2023005188A2 (es) | Compuestos y su uso en el tratamiento del cáncer | |
| DOP2021000198A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| CO2024000083A2 (es) | Pirrolo[2,3-d]pirimidinas sustituidas, su preparación y su aplicación terapéutica | |
| MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
| UY32782A (es) | COMPUESTOS DE PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDOS COMO INHIBIDORES DE TRK-QUINASA | |
| CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
| MX2021001096A (es) | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. | |
| NI201100100A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1. | |
| NZ596301A (en) | Novel 7-deazapurine nucleosides for therapeutic uses | |
| UY31638A1 (es) | Furo[3,2-c]piridina y tieno[3,2-c]piridinas | |
| NZ592608A (en) | Benzoxazole kinase inhibitors and methods of use | |
| BRPI0411863A (pt) | derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos | |
| EA201070841A1 (ru) | НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| DOP2004000949A (es) | Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos | |
| CO2018004933A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| MX2009003874A (es) | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| CY1124708T1 (el) | Φαρμακολογικως δραστικα αλικυκλικα υποκατεστημενα παραγωγα πυραζολο[1,5-a] πυριμιδινης | |
| ECSP088966A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. |